Sign in
4

Changes in Ownership

Summit Therapeutics Inc. Filed Acc 0000921895-20-003153

Chief Scientific Officer sold 43,282 shares at an average $4.41 ($190,694)

  • Chief Scientific Officer acquired 43,282 shares (option exercise)

From the SEC's structured data for this filing

Trades in this filing

Insider Date Transaction Shares Price Value Owned after D/I
Powell David Jonathan Chief Scientific Officer 2020-11-27 Option exercise +16,616 $1.92 $31,903 16,616 D
Powell David Jonathan Chief Scientific Officer 2020-11-27 Option exercise +12,953 $1.79 $23,186 29,569 D
Powell David Jonathan Chief Scientific Officer 2020-11-27 Sale −29,569 $4.39 $129,808 0 D
Powell David Jonathan Chief Scientific Officer 2020-11-30 Option exercise +13,713 $1.79 $24,546 13,713 D
Powell David Jonathan Chief Scientific Officer 2020-11-30 Sale −13,713 $4.44 $60,886 0 D
Derivatives
Powell David Jonathan Chief Scientific Officer 2020-11-27 Option exercise · Stock Option (right to buy) −16,616 $1.92 $31,903 417,639 D
Powell David Jonathan Chief Scientific Officer 2020-11-27 Option exercise · Stock Option (right to buy) −12,953 $1.79 $23,186 404,686 D
Powell David Jonathan Chief Scientific Officer 2020-11-30 Option exercise · Stock Option (right to buy) −13,713 $1.79 $24,546 390,973 D
Open-market sales · 43,282 sh · avg $4.41 · $190,694
Loading xslF345X03/form412566003_12012020.xml…